STOCKHOLM, Sept. 29, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that lecanemab (Leqembi) has been approved for once every four weeks intravenous (IV) maintenance dosing for the treatment of early Alzheimer's disease by the National...
Hence then, the article about leqembi approved for iv maintenance treatment in china was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Leqembi® approved for IV maintenance treatment in China )
Also on site :
- We Asked 4 Psychologists the Best Phrase To Use With Adult Children To Transform Your Relationship—They All Said the Same Thing
- Trump celebrates 80th birthday with a UFC fight at the White House as Americans pay the price for his Iran war
- Republican attorneys general urge EPA to classify mifepristone as water contaminant